Phase 1 Trial of IMAB027 in Patients With Recurrent Advanced Ovarian Cancer (OVAR)
- First Posted Date
- 2014-02-04
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Ganymed Pharmaceuticals GmbH
- Target Recruit Count
- 42
- Registration Number
- NCT02054351
- Locations
- 🇩🇪
UKSH Kiel, Kiel, Schleswig-Holstein, Germany
🇩🇪Nationales Centrum für Tumorerkrankungen (NCT) Heidelberg, Universitätsklinikum Heidelberg, Heidelberg, Baden-Württemberg, Germany
🇧🇪UZ Brussels, Brussels, Belgium
Efficacy and Safety Study of Multiple Doses of IMAB362 in Patients With Advanced Gastroesophageal Cancer
- First Posted Date
- 2010-09-09
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Ganymed Pharmaceuticals GmbH
- Target Recruit Count
- 54
- Registration Number
- NCT01197885
- Locations
- 🇧🇬
Complex Oncology Center, Veliko Turnovo, Bulgaria
🇧🇬MHAT "St.Marina", Varna, Bulgaria
🇩🇪Universitätsklinikum Halle, Halle, Germany
Safety and Tolerability Study of Claudiximab in Patients With Advanced Gastroesophageal Cancer
- First Posted Date
- 2009-05-27
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Ganymed Pharmaceuticals GmbH
- Target Recruit Count
- 15
- Registration Number
- NCT00909025
- Locations
- 🇱🇻
Piejuras Hospital, Liepaja, Latvia
🇱🇻Pauls Stradins University, Riga, Latvia
🇩🇪Universitätsklinikum Essen, Innere Klinik (Tumorforschung), Essen, Germany
© Copyright 2024. All Rights Reserved by MedPath